Roberto Finocchiaro

Dr. Roberto Finocchiaro


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 February 2023 in Biomedicines
Verified
Journal Article
Open access
PDF file
Maria Felicia FaienzaMaria Felicia Faienza
Maria Felicia Faienza
ATAlbina Tummolo
Albina Tummolo
MCMauro Celli
Mauro Celli
RFRoberto Finocchiaro
Roberto Finocchiaro
LPLaura Piacente
Laura Piacente
PDPatrizia D’eufemia
Patrizia D’eufemia
Brain-type creatine kinase (CK-BB) increases during osteoclastogenesis, with high circulating amounts in type I osteogenesis imperfecta (OI) following treatment with neridronate, a bisphosphonate able to inhibit osteoclast activity and survival. The aim of this study was to demonstrate the correlation between osteoclastogenesis and CK-BB release from OI patients’ osteoclasts treated with different concentrations of neridronate. Our patients showed reduced bone quality, increased levels of CTX I, a marker of bone resorption, and decreased levels of OPG, an inhibitor of osteoclastogenesis. In OI patients, the presence of MCSF and RANKL determined an increased secretion of CK-BB from osteoclasts (p = 0.04) compared with control conditions without these cytokines; interestingly, in the absence of these factors, the secretion of CK-BB is significantly elevated at 3 µmol/L compared with 0.03 and 1 µmol/L (p = 0.007). In healthy donors’ cultures, the higher concentration of CK-BB can be detected following stimulation with 3 µmol/L neridronate compared with the untreated condition both with and without MCSF and RANKL (p = 0.03 and p = 0.006, respectively). Consistently, in osteoclast cultures, neridronate treatment is associated with a decrease in multinucleated TRAP+ cells, together with morphology changes typical of apoptosis. Consistently, in the media of the same osteoclast cultures, we demonstrated a significant increase in caspase-3 levels. In conclusion, our findings support the idea that CK-BB levels increase in the serum of OI-treated patients.

19 July 2016
Verified
Book Chapter
Closed access
PDF file
PDPatrizia D’eUfemia
Patrizia D’eUfemia
MCMauro Celli
Mauro Celli
AZAnna Zambrano
Anna Zambrano
RFRoberto Finocchiaro
Roberto Finocchiaro